Cargando…

'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation

Psoriasis is an immune-mediated dermatosis characterized by T-lymphocyte-mediated epidermal hyperplasia, for which there are currently no effective clinical treatments. 'Psoriasis 1' is a Chinese herbal medicine formulation that has been recently used extensively in China for treating pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yang, Sun, Wen, Cha, Xushan, Wang, Hailong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447312/
https://www.ncbi.nlm.nih.gov/pubmed/32945358
http://dx.doi.org/10.3892/ijmm.2020.4695
_version_ 1783574270814715904
author Gao, Yang
Sun, Wen
Cha, Xushan
Wang, Hailong
author_facet Gao, Yang
Sun, Wen
Cha, Xushan
Wang, Hailong
author_sort Gao, Yang
collection PubMed
description Psoriasis is an immune-mediated dermatosis characterized by T-lymphocyte-mediated epidermal hyperplasia, for which there are currently no effective clinical treatments. 'Psoriasis 1' is a Chinese herbal medicine formulation that has been recently used extensively in China for treating patients with psoriasis. However, the molecular mechanism of action of this potent formulation has not yet been fully elucidated. In the present study, the effects of 'Psoriasis 1' on T ymphocytes in patients with psoriasis were investigated and the underlying molecular mechanism was discussed. Blood samples were collected from 40 patients with psoriasis. ELISA was employed to assess the levels of tumour necrosis factor-α, interferon-γ, interleukin (IL)-2, IL-6, transforming growth factor-β, IL-4, IL-12, IL-23 and vitamin D (VD). Western blot and quantitative PCR analyses were used to investigate the expression levels of VD receptor (VDR) and signal transducer and activator of transcription (STAT)4 in T lymphocytes. 'Psoriasis 1' was observed to significantly increase CD4(+) T cells. It also notably upregulated the mRNA and protein expression of VDR, and downregulated the mRNA and protein expression of STAT4. Moreover, the suppression of VDR was found to aggravate the inflammatory response, which was reversed by 'Psoriasis 1.' Thus, this formulation reportedly decreased the inflammation mediated by T lymphocytes in patients with psoriasis through inhibiting VDR-mediated STAT4 inactivation.
format Online
Article
Text
id pubmed-7447312
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-74473122020-08-28 'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation Gao, Yang Sun, Wen Cha, Xushan Wang, Hailong Int J Mol Med Articles Psoriasis is an immune-mediated dermatosis characterized by T-lymphocyte-mediated epidermal hyperplasia, for which there are currently no effective clinical treatments. 'Psoriasis 1' is a Chinese herbal medicine formulation that has been recently used extensively in China for treating patients with psoriasis. However, the molecular mechanism of action of this potent formulation has not yet been fully elucidated. In the present study, the effects of 'Psoriasis 1' on T ymphocytes in patients with psoriasis were investigated and the underlying molecular mechanism was discussed. Blood samples were collected from 40 patients with psoriasis. ELISA was employed to assess the levels of tumour necrosis factor-α, interferon-γ, interleukin (IL)-2, IL-6, transforming growth factor-β, IL-4, IL-12, IL-23 and vitamin D (VD). Western blot and quantitative PCR analyses were used to investigate the expression levels of VD receptor (VDR) and signal transducer and activator of transcription (STAT)4 in T lymphocytes. 'Psoriasis 1' was observed to significantly increase CD4(+) T cells. It also notably upregulated the mRNA and protein expression of VDR, and downregulated the mRNA and protein expression of STAT4. Moreover, the suppression of VDR was found to aggravate the inflammatory response, which was reversed by 'Psoriasis 1.' Thus, this formulation reportedly decreased the inflammation mediated by T lymphocytes in patients with psoriasis through inhibiting VDR-mediated STAT4 inactivation. D.A. Spandidos 2020-10 2020-08-06 /pmc/articles/PMC7447312/ /pubmed/32945358 http://dx.doi.org/10.3892/ijmm.2020.4695 Text en Copyright: © Gao et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Gao, Yang
Sun, Wen
Cha, Xushan
Wang, Hailong
'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation
title 'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation
title_full 'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation
title_fullStr 'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation
title_full_unstemmed 'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation
title_short 'Psoriasis 1' reduces T-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin D receptor-mediated STAT4 inactivation
title_sort 'psoriasis 1' reduces t-lymphocyte-mediated inflammation in patients with psoriasis by inhibiting vitamin d receptor-mediated stat4 inactivation
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447312/
https://www.ncbi.nlm.nih.gov/pubmed/32945358
http://dx.doi.org/10.3892/ijmm.2020.4695
work_keys_str_mv AT gaoyang psoriasis1reducestlymphocytemediatedinflammationinpatientswithpsoriasisbyinhibitingvitamindreceptormediatedstat4inactivation
AT sunwen psoriasis1reducestlymphocytemediatedinflammationinpatientswithpsoriasisbyinhibitingvitamindreceptormediatedstat4inactivation
AT chaxushan psoriasis1reducestlymphocytemediatedinflammationinpatientswithpsoriasisbyinhibitingvitamindreceptormediatedstat4inactivation
AT wanghailong psoriasis1reducestlymphocytemediatedinflammationinpatientswithpsoriasisbyinhibitingvitamindreceptormediatedstat4inactivation